ArticleNAM journal2026
R3ACT: An Oxygen-Controlled Biosensor-Based NAM to Support Animal-Free Chemical Safety Assessment.
Article in NAM journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most in vitro chemical safety workflows are performed in ambient air, although many human tissues experience substantially lower physiological oxygen levels. This mismatch can alter redox tone, stress-response signaling, and interpretation of chemical effects. Here, we present R3ACT (Redox & Antioxidant Capacity Tracker), an animal-free, oxygen-controlled live-cell NAM for mechanistic profiling of redox perturbation and antioxidant-response activation. In human HaCaT keratinocytes adapted to 5 kPa O₂, R3ACT combines viability-gated concentration selection, oxygen-controlled plate-reader measurements, high-content microscopy, and deep-learning-assisted single-cell analysis. The workflow integrates cytosolic and mitochondrial HyPer7.2 biosensors for H₂O₂ dynamics with POINTER, an Nrf2 transcriptional reporter, to assess antioxidant-response engagement. As proof of concept, four exposure-relevant materials were profiled in the main screen, with iron formulations assessed as additional pharmaceutical case examples. Zinc oxide produced the strongest reproducible Nrf2 activation across two independent runs, confirmed by single-cell microscopy. Polystyrene nanoplastics likewise showed reproducible, microscopy-confirmed Nrf2 activation, whereas perfluorooctanoic acid showed a borderline response that was not confirmed by microscopy. Salicylic acid induced Nrf2 activation under physiological oxygen and was interpreted as antioxidant-response engagement rather than skin-sensitization classification. HyPer7.2 provided compartment-specific mechanistic context, but often revealed transient fluctuations rather than consistent material-induced H₂O₂ increases. Together, these data position R3ACT as an early-stage, oxygen-controlled NAM that may support animal-free chemical and drug-screening workflows by generating mechanistic redox/Nrf2 response profiles for compound prioritization. Further benchmarking, predefined performance criteria, and inter-laboratory studies are required before regulatory applicability can be assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.